- Paolo Bruzzi, National Cancer Research Institute
- Ian Cree, Warwick Medical School, Coventry
- Shoukat Dedhar, British Columbia Cancer Agency
- John A Hartley, University College London
- Manami Inoue, University of Tokyo
- Ferdinando Mannello, University Carlo Bo
- Mark McKeage, University of Auckland
- Christophe Nicot, Kansas University Medical Center
- Stephen P Povoski, The Ohio State University
- Charles Rosser, University of Hawaii Cancer Center
- Dirk Vordermark, Martin Luther University Halle-Wittenberg
- Dafne Solera, BioMed Central
18F-fluorodeoxyglucose (18F-FDG) PET/CT can be successfully performed at extended injection-to-scan acquisition times while maintaining diagnostic image quality and has potential for real-time use of 18F-FDG PET/CT imaging in conjunction with interventional and surgical procedures.
Lipid metabolism enzyme ACSVL3 supports the malignant phenotype of glioblastoma cancer stem cells, promotes their ability to initiate and propagate tumors and may serve as a therapeutic target for brain cancer treatment.
The relationship between human papillomavirus (HPV) type-specific viral load, integration and methylation status and disease stage supports the potential use of viral load and methylation, but not integration, as biomarkers of cervical disease.
The expression of Matrix metalloproteinase-10 (MMP10) is associated with the upregulation of molecules related to angiogenesis, metastasis, and apoptosis, suggesting that MMP10 may play a role in cervical cancer progression.
Salvatore Micali and colleagues review recent findings on the extra-thyroidal expression of the sodium iodide symporter (NIS) and discuss its potential use as a biomarker and therapeutic tool in breast and urological cancer.
High expression of somatostatin receptors can be exploited for molecular imaging of Merkel cell carcinoma with high sensitivity especially for bone, soft tissue and brain metastases.
An alternative promoter drives expression of four novel transcript variants of AKT1 in human breast cancer cells and may contribute to the increased expression of this kinase in many cell lines and primary breast cancers.
Changes in chromatin density and heterochromatin structure that occur very early during carcinogenesis can be detected and measured by transmission electron microscopy and may lead to the establishment of new biomarkers.
BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.
BMC Cancer is part of the BMC series which publishes subject-specific journals focused on the needs of individual research communities across all areas of biology and medicine. We offer an efficient, fair and friendly peer review service, and are committed to publishing all sound science, provided that there is some advance in knowledge presented by the work.
BMC series - open, inclusive and trusted.
Join the Editorial Board!
Are you interested in becoming an Editorial Board member for BMC Cancer and helping to maintain the editorial standards and ethos of this growing journal? To volunteer as an Associate Editor, please simply contact us at email@example.com, enclosing a summary of your research interests and relevant expertise. We look forward to hearing from you.
Christudas Morais, David W Johnson, David A Vesey, and Glenda C Gobe1BMC Cancer 2013, 13:14 (10 January 2013)
Section Editor's profile
Mark McKeage is a medical oncologist and associate professor in the department of pharmacology and clinical pharmacology and co-director of the Auckland Cancer Society Research Centre at the university of Auckland, New Zealand. His current research focuses on how membrane transporters determine response and handling of platinum-based anticancer drugs. In addition, he leads a programme of phase I oncology trials at his centre.
"BMC Cancer is the leading Open Access international journal in the field of oncology. By publishing over 500 articles per year, BMC Cancer offers rapid dissemination of the most recent information of interest to the broad oncology science community."
Prof McKeage is the Section Editor of the Clinical oncology- medical oncology and pharmacology section of BMC Cancer.